Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Nivolumab + Ramucirumab
Indication/Tumor Type gastric adenocarcinoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastric adenocarcinoma not applicable Nivolumab + Ramucirumab Phase Ib/II Actionable In a Phase I/II trial, Cyramza (ramucirumab) and Opdivo (nivolumab) combination treatment resulted in a disease control rate of 59% (27/46) and partial response in 22% (10/46) of patients with previously treated advanced gastric adenocarcinoma, with a PD-L1 positive rate of 44% (J Clin Oncol 36, 2018 (suppl; abstr 4047); NCT02999295). detail...
PubMed Id Reference Title Details
Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study). Full reference...